0000899243-21-007386.txt : 20210219
0000899243-21-007386.hdr.sgml : 20210219
20210219162618
ACCESSION NUMBER: 0000899243-21-007386
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20201203
FILED AS OF DATE: 20210219
DATE AS OF CHANGE: 20210219
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Harding Thomas C.
CENTRAL INDEX KEY: 0001834833
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35347
FILM NUMBER: 21656302
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY, SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clovis Oncology, Inc.
CENTRAL INDEX KEY: 0001466301
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 900475355
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
BUSINESS PHONE: (303) 625-5000
MAIL ADDRESS:
STREET 1: 5500 FLATIRON PARKWAY
STREET 2: SUITE 100
CITY: BOULDER
STATE: CO
ZIP: 80301
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2020-12-03
2020-12-07
0
0001466301
Clovis Oncology, Inc.
CLVS
0001834833
Harding Thomas C.
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100
BOULDER
CO
80301
0
1
0
0
See Remarks
Common Stock
1976
I
By wife
Stock Option (right to buy)
76.65
2027-09-01
Common Stock
6000
I
By wife
Stock Option (right to buy)
8.29
2030-01-31
Common Stock
500
I
By wife
Restricted Stock Units
2028-03-01
Common Stock
93
I
By wife
Restricted Stock Units
2029-02-01
Common Stock
1250
I
By wife
Restricted Stock Units
2030-01-31
Common Stock
2900
I
By wife
These shares were omitted from the reporting person's original Form 3, and also were omitted from two Forms 4 filed by the reporting person after his original Form 3 was filed.
On September 5, 2017, the reporting person was granted 6,000 options. The option vested as to 25% of the shares on September 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3.
On January 31, 2020, the reporting person was granted 500 options. The option vested as to 25% of the shares on January 31, 2021, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3.
On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3.
On February 1, 2019, the reporting person was granted 2,500 Restricted Stock Units. 50% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests on February 1, 2021. These shares were omitted from the reporting person's original Form 3.
On January 31, 2020, the reporting person was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vests on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3.
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Senior Vice President and Chief Scientific Officer
/s/ Thomas C. Harding
2021-02-19